GlassScriptPhysician profile
Matthew Daniel Acampora
NPI 1497728174
$13,657.60
in general payments reported to CMS, 2019-2025
73 companies · $1,459 in 2025
The $1,459 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $942 · 2021: $3,213 · 2022: $2,842 · 2023: $2,603 · 2024: $2,490 · 2025: $1,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,491 · Education: $60.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,491.25 |
| Education | $60.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,194.37 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,625.73 | 2020-2025 | Linzess, Ubrelvy, Viberzi |
| Lilly USA, LLC | $710.65 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $658.91 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $582.62 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.54 | 2020-2025 | Jardiance, Synjardy |
| Bausch Health US, LLC | $495.59 | 2019-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $476.12 | 2020-2024 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $416.60 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $321.71 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $296.94 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $289.57 | 2022 | |
| Merck Sharp & Dohme LLC | $278.92 | 2020-2023 | Verquvo, Belsomra |
| Amgen INC. | $269.57 | 2020-2025 | Repatha, Evenity, Otezla |
| Eisai INC. | $230.58 | 2020-2021 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Acampora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.